D016393DisordersC04.557.386.480.150C15.604.515.569.480.150C20.683.515.761.480.150631030.912458Lymphoma, B-Cellplugins:TwitterTwitterprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMedicine-Hematology and OncologyAnandPatelAnand Patel41.7886000000000087.598699999999994043Patel, Anand0000-0002-0296-8686Assistant Professor36240471Alban J, DuVall A, Gurbuxani S, Stock W, Patel AAJCO precision oncologyOutcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.JCO Precis Oncol2022-10-01T00:00:002022Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.3.42570.0060339163research area of0.9836250.0264513105subject area for36006670Venkataraman G, Alikhan MBBloodNumerous B cells in a mediastinal mass, but not a B-cell lymphoma. Blood. 2022 08 25; 140(8):932.Blood2022-08-25T00:00:002022Numerous B cells in a mediastinal mass, but not a B-cell lymphoma.36691748Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, Stock W, Jabbour EJAmerican journal of hematologySequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.Am J Hematol2023-02-06T00:00:002023Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.https://imagebank.hematology.org/ASH Image Bank@gvencut1anand_88_patelPathologyUniversity of ChicagoSonaliSmithxG1nCq0cOfnamXNnYUHhvWD+6g==Sonali Smith41.78927490000000-87.601250000000002364Smith, SonaliProfessor37923249Weiss J, Gibbons K, Ehyaee V, Perez-Silos V, Zevallos A, Maienschein-Cline M, Brister E, Sverdlov M, Shah E, Balakrishna J, Symes E, Frederiksen JK, Gann PH, Post R, Lopez-Hisijos N, Reneau J, Venkataraman G, Bailey N, Brown NA, Xu ML, Wilcox RA, Inamdar K, Murga-Zamalloa CThe American journal of pathologySpecific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune Surveillance Program. Am J Pathol. 2024 Jan; 194(1):165-178.Am J Pathol2023-11-03T00:00:002023Specific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune Surveillance Program.38244272Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee H, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Snedeker J, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNWaldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 01; 22(1D):e240001.J Natl Compr Canc Netw2024-01-01T00:00:002024Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.true1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessor1010PeterRiedellx3BgDqUQFeD5hHlsaUXv9Gq0+s+oPeter Riedell0.000000000000000.000000000000003359Riedell, PeterAssociate ProfessorGirishVenkataraman0HRsBaoUDczMknJtY0fp/Cv/+94=Girish Venkataraman0.000000000000000.000000000000002713Venkataraman, GirishProfessorDanielArberDaniel Arber0.000000000000000.000000000000003406Arber, DanielProfessor